Publications by authors named "J Hiemenz"
This case is a rare presentation of severe aplastic anemia in a 31-year-old male with acquired clonality of the X chromosome as the sole cytogenetic abnormality. This abnormality has not been reported to our knowledge, and the significance of this finding remains unclear. Comprehensive diagnostic workup included bone marrow biopsy, cytogenetic analysis, and Next-Generation sequencing, which revealed no tier I/II variants typically associated with clonal hematopoietic disorders.
View Article and Find Full Text PDFA phase 1b study was conducted to evaluate the safety and feasibility of ciprofloxacin and etoposide combination treatment in subjects with relapsed and refractory acute myeloid leukemia. Eleven subjects were enrolled in the study. Utilizing the standard '3 + 3' design, escalating ciprofloxacin doses (750 mg, 1000 mg) twice daily on D1-D10 in combination with a fixed dose (200 mg) of etoposide on D2-D8 were administered.
View Article and Find Full Text PDFArticle Synopsis
- - The text discusses two difficult cases of cardiac transthyretin amyloidosis that were initially misdiagnosed as cardiac amyloidosis due to light chain issues linked to active myeloma.
- - An endomyocardial biopsy combined with mass spectrometry was crucial for accurately diagnosing the condition.
- - The correct diagnosis was important for guiding the appropriate treatment for these patients.
Article Synopsis
- Autologous hematopoietic stem cell transplantation (ASCT) can improve survival rates in multiple myeloma (MM), but some patients struggle to collect enough HSPCs using standard methods like G-CSF.
- The GENESIS trial tested a new drug, motixafortide, combined with G-CSF, against a placebo and G-CSF to see if it could help mobilize more HSPCs for ASCT.
- Results showed that motixafortide significantly increased the number of patients who collected sufficient HSPCs, outperforming the placebo group, and its side effects were generally mild and manageable.
Immune effector cell-associated neurotoxicity syndrome (ICANS) secondary to chimeric antigen receptor T-cell therapy is common in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), but imaging findings during neurologic toxicity and their meaning have yet to be systematically described in this patient population. Brexucabtagene autoleucel (brexu-cel) is a CD19-directed autologous T-cell immunotherapy for the treatment of adult patients with R/R B-cell ALL that can enter the central nervous system. We present a case of an adult patient with R/R B-cell ALL and prior leptomeningeal disease who developed neurologic toxicity and new findings on magnetic resonance imaging of the brain while receiving brexu-cel.
View Article and Find Full Text PDF